PPT-Module 4: Mineral and Bone Disease in Chronic Kidney Disease

Andrew Narva MD FASN amp Amy Barton Pai PharmD MHI FASN FCCP FNKF Andrew Narva MD FASN No financial disclosuresconflicts of interest Amy Barton Pai PharmD MHI FASN FCCP FNKF. Kevin Harley, M.D.. Assistant Clinical Professor. Department of Medicine. Division of Nephrology & Hypertension. UC Irvine Medical Center. Objectives. Review Definition of CKD and its classification. Epidemiology. CKD affects about 26 million people in the US. Approximately 19 million adults are in the early stages of the disease . On the rise do to increasing prevalence of diabetes and hypertension. Epidemiology. CKD affects about 26 million people in the US. Approximately 19 million adults are in the early stages of the disease . On the rise do to increasing prevalence of diabetes and hypertension. Chronic Kidney Disease: Detection and Management in Primary Care Julia Scialla, MD, MHS, FASN Associate Professor of Medicine and Public Health Sciences University of Virginia Adjunct Associate Professor of Medicine Chronic Kidney Failure Done by : Resources : Objectives : Extra Book Notes Important Golden Notes Differentiate Chronic kidney disease-CKD from Acute Kidney Injury-AKI. Dr. T. A. L. . Dlamini. Specialist Physician and . Nephrologist. Talk overview . Kidney function. Assessing kidney function. Chronic kidney disease (CKD). Benefits of early detection . Conclusion and take home message . Andrew . Narva. , MD, FASN & . Amy Barton . Pai. , PharmD, MHI, FASN, FCCP, FNKF. Andrew . Narva. , MD, FASN. No financial disclosures/conflicts of interest. Amy Barton . Pai. , PharmD, MHI, FASN, FCCP, FNKF. . Renal Pharmacy Beginners Guide lecture 2 . P. rovide an introduction to the management of chronic kidney disease . Key aims of treatment in CKD. Risk factors for CKD . Frequently prescribed medication. Namita Singh, MD, FASN. Year 2021. DISCLOSURES. I have no financial relationships with commercial interests to disclose.. This presentation does not include discussion of off-label or investigational use. . Chronic . c. are . Training . For . district . hospital . Nurses . in . Rwanda . 2013. Session 1: Defining chronic kidney disease. By the end of this Session, participants will be able to:. Screen for chronic kidney disease. . Structural . or functional abnormalities of the kidneys for . >. 3 months. . from early to late-stage disease, . Chronic Kidney Disease. as . manifested by either:. 1. Kidney . damage, with or without decreased GFR, as . Quality Department Guidelines for Clinical Care Ambulatory Chronic Kidney Disease Guideline Team Team Leader Jennifer Reilly Lukela, MD General MedicineTeam MembersR. Van Harrison, PhDMedical Educati IntroductionFabry disease (FD) arises from an X-linked defect in lipid storage, whereby deicient or -galactosidase A (-gal A) activity leads to systemic deposition of glyco-sphingolipids, mainly Dr Jean . Filipov. , PhD. UH . Alexandrovska. Sofia, Bulgaria. Plan of the presentation. Biochemical abnormalities after kidney transplantation (KT). Bone disease after KT. Vascular involvement after KT.